Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2004 2
2005 2
2006 3
2007 2
2008 3
2009 5
2010 7
2011 7
2012 4
2013 2
2014 3
2015 6
2016 7
2017 8
2018 6
2019 10
2020 9
2021 12
2022 10
2023 8
2024 2

Text availability

Article attribute

Article type

Publication date

Search Results

101 results

Results by year

Filters applied: . Clear all
Page 1
Correction: Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer.
Ganci F, Allegretti M, Frascolla C, Spinella F, Rollo F, Sacconi A, De Pascale V, Palcau AC, Manciocco V, Vescovo M, Cotroneo E, Blandino F, Benevolo M, Covello R, Muti P, Strano S, Vidiri A, Fontemaggi G, Pellini R, Blandino G. Ganci F, et al. Among authors: vidiri a. Biomark Res. 2024 Mar 26;12(1):37. doi: 10.1186/s40364-024-00582-0. Biomark Res. 2024. PMID: 38532476 Free PMC article. No abstract available.
Combined TP53 status in tumor-free resection margins and circulating microRNA profiling predicts the risk of locoregional recurrence in head and neck cancer.
Ganci F, Allegretti M, Frascolla C, Spinella F, Rollo F, Sacconi A, Valentina P, Palcau AC, Manciocco V, Vescovo M, Cotroneo E, Blandino F, Benevolo M, Covello R, Muti P, Strano S, Vidiri A, Fontemaggi G, Pellini R, Blandino G. Ganci F, et al. Among authors: vidiri a. Biomark Res. 2024 Mar 5;12(1):32. doi: 10.1186/s40364-024-00576-y. Biomark Res. 2024. PMID: 38444004 Free PMC article.
Radiomics and artificial intelligence analysis by T2-weighted imaging and dynamic contrast-enhanced magnetic resonance imaging to predict Breast Cancer Histological Outcome.
Petrillo A, Fusco R, Barretta ML, Granata V, Mattace Raso M, Porto A, Sorgente E, Fanizzi A, Massafra R, Lafranceschina M, La Forgia D, Trombadori CML, Belli P, Trecate G, Tenconi C, De Santis MC, Greco L, Ferranti FR, De Soccio V, Vidiri A, Botta F, Dominelli V, Cassano E, Boldrini L. Petrillo A, et al. Among authors: vidiri a. Radiol Med. 2023 Nov;128(11):1347-1371. doi: 10.1007/s11547-023-01718-2. Epub 2023 Oct 6. Radiol Med. 2023. PMID: 37801198
Pretreated EGFRdel19/BRAFV600E Lung Adenocarcinoma With Leptomeningeal Disease Achieving Long-Lasting Disease Control on Osimertinib, Dabrafenib, and Trametinib: A Case Report.
Orciuolo C, Cappuzzo F, Landi L, Resuli B, Carpano S, Vidiri A, Buglioni S, Mandoj C, Ciliberto G, Minuti G. Orciuolo C, et al. Among authors: vidiri a. JTO Clin Res Rep. 2023 Jun 30;4(8):100545. doi: 10.1016/j.jtocrr.2023.100545. eCollection 2023 Aug. JTO Clin Res Rep. 2023. PMID: 37533438 Free PMC article.
Combi-TED: a new trial testing Tedopi® with docetaxel or nivolumab in metastatic non-small-cell lung cancer progressing after first line.
Landi L, Delmonte A, Bonetti A, Pasello G, Metro G, Mazzoni F, Borra G, Giannarelli D, Andrikou K, Mangiola D, Gori S, D'Andrea MR, Minuti G, Resuli B, Laudisi A, Vidiri A, Conti L, Cappuzzo F. Landi L, et al. Among authors: vidiri a. Future Oncol. 2022 Dec;18(40):4457-4464. doi: 10.2217/fon-2022-0913. Epub 2023 Mar 22. Future Oncol. 2022. PMID: 36946237
101 results